Sector News

Sarepta sees muscle function gains with DMD gene therapy

October 5, 2018
Life sciences

Sarepta’s case for its Duchenne muscular dystrophy (DMD) gene therapy is getting stronger, with early data now linking its effects on a critical protein with improved muscle function.

An earlier readout from the phase 1/2 trial in June from three patients treated with the gene therapy showed that it increased levels of microdystrophin—a truncated version of the dystrophin protein which is missing in DMD—and a fourth patient has now shown “robust” expression levels, says the company.

At the time, Sarepta said it was confident that the increases were enough to hold back the progressive muscle damage that characterizes the disease, but at the time it was relying purely on biomarkers such as serum creatine kinase (CK)—a sign of muscle damage—to gauge its effects. Now, it says the new data show functional improvements for all four patients on measures such as their ability to climb stairs, get up from the floor or walk 100 meters.

The trial’s lead investigator, Jerry Mendell, M.D., of Nationwide Children’s Hospital, is cautious in his assessment of those improvements, saying: “while results suggest functional improvements across all measures significantly greater than natural history predictions, … this is a small, uncontrolled data set and these positive results must be reconfirmed in the larger, controlled registration trial.”

Nevertheless, it’s another baby step forward for the AAVrh74.MHCK7.micro-dystrophin program and the first time that a gene therapy has been shown to improve symptoms in DMD.

Encouragingly, the fourth patient also showed CK reductions alongside the increases in microdystrophin, with the group as a whole showing a 78% cut from baseline on that surrogate marker. Sarepta also presented new data showing that the microdystrophin was being expressed as intended mainly within the sarcolemma of skeletal muscles.

Shares in Sarepta wobbled a bit after the data was released, perhaps because of some variability in microdystrophin levels and particularly an unexpectedly high increase in patient four. It closed a little over 3% higher after investors sifted through the data, however, and added another 5% in after-hours trading.

The company’s share price has been climbing steadily for the last few months as the gene therapy program progressed, slipping back briefly after the FDA placed it on a clinical hold in July on a quality blip, only to remove it two months later.

Sarepta CEO Doug Ingram acknowledged that the data so far is preliminary, but said it has “strengthened our resolve to rapidly move to a confirming trial and, assuming successful, to bring this therapy to the Duchenne community around the world with a sense of urgency.”

By: Phil Taylor

Source: Fierce Biotech

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend